Citron Research executive editor Andrew Left, explains his trading is not relevant to the Valeant story.
Citron’s Andrew Left tight-lipped on Valeant position
Citron’s Left: I put out info that was true
Citron Research executive editor Andrew Left, addresses Valeant Pharmaceuticals’ critical response to his report on the company.
Citron: Not contacted by SEC
Citron Research executive editor Andrew Left, discusses the company’s strategy with the Valeant story and the Enron analogy.
Citron: Valeant should be the focus, not us
Citron Research executive editor Andrew Left, discusses the company’s strategy with the Valeant story in an effort to walk away from the story.
Citron: Easier to pass Citron story to mainstream media
Citron Research executive editor Andrew Left, discusses the company’s strategy with the Valeant story.
